Assistant Professor, Pathology, Ohio State University College of Medicine
Pathology
Dr. Gerard Lozanski, MD
|
|
Give Review
Gerard Lozanski practices Pathology. Gerard Lozanski has written publications. He has 64 publications published with PubMed. The lastest paper is: 'The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic Leukemia.
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic Leukemia patients.
- Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
- Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic Leukemia treated with fludara...
- The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development.
- Cotreatment of hairy cell Leukemia and melanoma with the BRAF inhibitor dabrafenib.
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- A phase 1/1b study of combined rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed/refractory non-Hodgkin's Lymphoma.
- Reduced dose pentostatin for initial management of hairy cell Leukemia patients who have active infection or risk of hemorrhage is safe and effective.
- A phase I trial of the Fc engineered CD19 antibody XmAb®5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic Leukemia.
- The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
- Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin Lymphoma is associated with prolonged progression-free survival.
- Prolonged Lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Grou...
- The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine Leukemia model.
- Impact of targeted therapy on outcome of chronic lymphocytic Leukemia patients with relapsed del(17p13.1) karyotype at a single center.
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and Acute B cell malignancies.
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Ac...
- Outcome of patients with relapsed or refractory chronic lymphocytic Leukemia treated with flavopiridol: impact of genetic features.
- Inter-reader variability in follicular Lymphoma grading: Conventional and digital reading.
- Characterization of a new chronic lymphocytic Leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
- Automatic detection of follicular regions in H&E images using iterative shape index.
- Collagenous gastritis: a case report, morphologic evaluation, and review.
- Synchronous occurrence of collagenous colitis and pseudomembranous colitis.
- The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen.
- C-reactive protein and serum amyloid A mRNA stability following induction by cytokines.
- Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum.
- Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms.
- IL-1 receptor antagonist affects the plasma protein response of Hep 3B cells to conditioned medium from lipopolysaccharide-stimulated monocytes.
- Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1?
- Binding of C-reactive protein (CRP) by human peripheral blood lymphocytes in vivo.
- Decreased concentrations of tumor necrosis factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis.
- Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein.
- Effect of flurbiprofen on cytokine production by human monocytes and U-937 and THP-1 cell lines.
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
- The spectrum of hematologic malignancies involving the pancreas: potential clinical mimics of pancreatic adenocarcinoma.
- Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.
- Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in Acute lymphoblastic leukemia cells.
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocyt...
- Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic Leukemia: justificatio...
- A clinicopathologic evaluation of follicular Lymphoma grade 3A versus grade 3B reveals no survival differences.
- Adult Burkitt Leukemia and lymphoma.
- Alemtuzumab is an effective therapy for chronic lymphocytic Leukemia with p53 mutations and deletions.
- Computer-aided classification of centroblast cells in follicular Lymphoma.
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell Lymphoma.
- Modern strategies for hairy cell Leukemia.
- Detection of follicles from IHC-stained slides of follicular Lymphoma using iterative watershed.
- Computer-aided detection of centroblasts for follicular Lymphoma grading using adaptive likelihood-based cell segmentation.
- The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy.
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple Myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
- Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-Leukemia effects, having low or absent calcemic activity.
- Extraction of color features in the spectral domain to recognize centroblasts in histopathology.
- Imaging mass spectrometry analysis for follicular Lymphoma grading.
- Feature-based registration of histopathology images with different stains: an application for computerized follicular Lymphoma prognosis.
- Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin Lymphoma.
- The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and Acute lymphoblastic leukemia in vitro and in vivo.
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic Leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic Leukemia c...
- Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic Leukemia.
- A novel Raji-Burkitt's Lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
- Phase I study of decitabine alone or in combination with valproic acid in Acute myeloid leukemia.
- Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts.
Schools
Karol Marcinkowski University of Medical Sciences
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
- Hematopathology
- Pathology
Accepted Insurances
Education
-
University of Medical Science Poznan
Hospital
-
Ohio State University Wexner Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427088756 |
| Last Name Of The Provider | LOZANSKI |
| First Name Of The Provider | GERARD |
| View All |
Similar Doctors
|
Dr. Peter J. Kourlas, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Leona B. Ayers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynette S. Bornman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samir Kahwash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica A. Hemminger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nye R. Larrimer, MD |
|
|
Dr. Martin L. Kelsten, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary H. Tozbikian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Habibe Kurt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nick P. Trifelos, MD |
|
|
Kathryn M. Clausen |